Safety of Tdap-IPV given one month after Td-IPV booster in healthy young adults: a placebo-controlled trial
- PMID: 19011374
- DOI: 10.4161/hv.5.5.6911
Safety of Tdap-IPV given one month after Td-IPV booster in healthy young adults: a placebo-controlled trial
Abstract
Background: In France, the only vaccines available for use as a pertussis booster in adults are combined vaccines containing adsorbed tetanus, diphtheria (adult formulation), acellular pertussis and inactivated poliovirus (Tdap-IPV). Adults may require a pertussis booster relatively soon after having received vaccines containing tetanus-diptheria antigens (Td) (occupational or familial circumstances such as new job, childbirth in recent past or future), although the safety of Tdap-IPV when administered soon after vaccination with Td is undocumented.
Methods: In this randomized, double-blind, multi-centre study, we assessed the safety of Tdap-IPV administered one month after vaccination with tetanus, diphtheria (adult formulation), inactivated poliovirus vaccination (Td-IPV) in healthy adults vaccinated according to the French vaccination calendar (seven tetanus-diphtheria vaccinations by age 18 years). Subjects received either Td-IPV (n = 249) or placebo (n = 251) followed 1 month later by Tdap-IPV. Any adverse events (AEs) were recorded.
Results: The safety of Tdap-IPV was similar when Tdap-IPV vaccine was administered one month after either Td-IPV or placebo: at seven days, 85.1% versus 93.4% subjects reported at least one reaction at the injection site, mainly pain (82.6% versus 92.1%); 40.5% versus 45.0%, at least one systemic AE (mainly headache: 26.4% versus 26.0%); fever concerned 1.7% of both groups. No serious vaccine-related AEs were reported. Both safety profiles corresponded to documented product characteristics.
Conclusions: Tdap-IPV may be administered to adults one month after Td-IPV without exacerbating post-vaccination side-effects.
Similar articles
-
Adult formulation of a five component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine is safe and immunogenic in adolescents and adults.Pediatr Infect Dis J. 2000 Apr;19(4):276-83. doi: 10.1097/00006454-200004000-00003. Pediatr Infect Dis J. 2000. PMID: 10783014 Clinical Trial.
-
Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults.Vaccine. 2005 May 25;23(28):3657-67. doi: 10.1016/j.vaccine.2005.02.013. Vaccine. 2005. PMID: 15882526 Clinical Trial.
-
Immunogenicity and reactogenicity of a decennial booster dose of a combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and inactivated poliovirus booster vaccine (dTpa-IPV) in healthy adults.Vaccine. 2015 May 21;33(22):2594-601. doi: 10.1016/j.vaccine.2015.03.104. Epub 2015 Apr 14. Vaccine. 2015. PMID: 25882172 Clinical Trial.
-
Reduced-antigen, combined diphtheria-tetanus-acellular pertussis vaccine, adsorbed (Boostrix) US formulation): use as a single-dose booster immunization in adolescents aged 10-18 years.Paediatr Drugs. 2006;8(3):189-95; discussion 196. doi: 10.2165/00148581-200608030-00005. Paediatr Drugs. 2006. PMID: 16774298 Review.
-
Feasible improvements in vaccines in the Expanded Programme on Immunization.Rev Infect Dis. 1989 May-Jun;11 Suppl 3:S530-7. doi: 10.1093/clinids/11.supplement_3.s530. Rev Infect Dis. 1989. PMID: 2669097 Review.
Cited by
-
Vaccination in Pregnancy.Dtsch Arztebl Int. 2021 Apr 16;118(15):262-268. doi: 10.3238/arztebl.m2021.0020. Dtsch Arztebl Int. 2021. PMID: 34114547 Free PMC article. Review.
-
Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccines: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2019.MMWR Morb Mortal Wkly Rep. 2020 Jan 24;69(3):77-83. doi: 10.15585/mmwr.mm6903a5. MMWR Morb Mortal Wkly Rep. 2020. PMID: 31971933 Free PMC article.
-
The Effect of Pharmacy-Driven Education on the Amount of Appropriately Administered Tetanus Vaccines in the Emergency Department.Hosp Pharm. 2019 Feb;54(1):45-50. doi: 10.1177/0018578718769239. Epub 2018 Apr 18. Hosp Pharm. 2019. PMID: 30718934 Free PMC article.
-
Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP).MMWR Recomm Rep. 2018 Apr 27;67(2):1-44. doi: 10.15585/mmwr.rr6702a1. MMWR Recomm Rep. 2018. PMID: 29702631 Free PMC article.
-
Randomized Controlled Trial of the Safety and Immunogenicity of Revaccination With Tetanus-Diphtheria-Acellular Pertussis Vaccine (Tdap) in Adults 10 Years After a Previous Dose.J Pediatric Infect Dis Soc. 2019 May 11;8(2):105-114. doi: 10.1093/jpids/pix113. J Pediatric Infect Dis Soc. 2019. PMID: 29438562 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous